Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Last trade$12.17
Day change+$0.195 (+1.63%)
Day range$11.69 – $12.64
Volume819,601
Market cap$1.11B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for DRTS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for DRTS.
Recent news
Company coverage with links to the original publishers.
Alpha Tau Medical reported positive interim results from its REGAIN trial testing Alpha DaRT for recurrent glioblastoma treatment. All eight treated patients remain alive with a median follow-up of 6.9 months, 100% objective response rate in six evaluable patients (83.3% complete responses), 100% treatment feasibility, and no unanticipated serious adverse events. The company plans to continue enrollment toward 20 patients.
Alpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modular PMA application process. Alpha DaRT has received Breakthrough Device Designation from the FDA for this indication.
Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, discussing recent achievements and upcoming data milestones for their Alpha DaRT cancer therapy.
The global radiopharmaceuticals market is projected to grow at a CAGR of 10.3% from 2024 to 2030, driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the transition towards personalized medicine. North America and Asia-Pacific are the key regional markets.
Alpha Tau Medical Ltd. announced the appointment of Maya Netser to its Board of Directors, while Meir Jakobsohn is stepping down from the Board but will continue to serve as an advisor.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.